Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2007-04-09
2010-12-07
Marvich, Maria B (Department: 1633)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S202100, C424S205100, C435S455000, C435S456000, C435S091410, C435S091420
Reexamination Certificate
active
07846454
ABSTRACT:
The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.
REFERENCES:
patent: 5679342 (1997-10-01), Houghton et al.
patent: 6127116 (2000-10-01), Rice et al.
patent: 6153421 (2000-11-01), Yanagi et al.
patent: 7084266 (2006-08-01), Yanagi et al.
patent: 7201911 (2007-04-01), Yanagi et al.
patent: 2007/0141668 (2007-06-01), Yanagi et al.
patent: 0 516 270 (1992-12-01), None
patent: WO 97/08310 (1997-03-01), None
patent: WO 98/39031 (1998-09-01), None
Bassett, S.E. et al. (2001) “Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection.”Hepatology33:1479-1487.
Bigger, C.B. et al. (2001) “DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection.”J. Virol.75(15):7059-7066.
Bukh, J. et al. (2004) “Persistence of HCV after homologous monoclonal re-challenge is associated with emergence of virus variants.” In Jilbert AR, Grgacic EVL, Vickery K, Burrell CJ, Cossart YE, eds.Proceedings of the 11thInternational Symposium on Viral Hepatitis&Liver Disease. Australian Centre for Hepatitis Virology, pp. 375-377.
Dash, S. et al. (1997) “Transfection of HepG2 cells with infectious hepatitis C virus genome.”Am. J. Pathol. 151:363-373.
Farci, P. et al. (1996). “Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.”PNAS USA93:15394-15399.
Fausto, N. (1997) “Replication of hepatitis C virus in tissue culture: a potential breakthrough in need of confirmation.”Am. J. Pathol.151:361.
Forns, X. et al. (2002) “The challenge of developing a vaccine against hepatitis C virus. ”J. Hepatol.37:684-695.
Honda, M. et al. (1996) Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA.Virology222:31-42, Aug. 1996.
Inchauspe, G. et al. (1991) “Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates.”PNAS USA88:10292-10296.
Kolykhalov, A.A. et al. (1996) “Identification of a highly conserved sequence element at he 3' terminus of hepatitis C virus genome RNA”J. Virol.70, 3363-3371.
Kolykhalov, A.A. et al. (1997) “Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA.”Science277:570-574.
Kolykhalov, A.A. et al. (2000) “Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo.”J. Virol.74:2046-2051.
Lanford, R.E. et al. (2004) “Cross-genotype immunity to hepatitis C virus.”J. Virol.78(3):1575-1581.
Lindenbach, B.D. et al. (2006) “Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro.”PNAS USA103:3805-3809.
Major, M.E. et al. (2002) “Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge.”J. Virol.76(13):6586-6595.
Major, M.E. et al. (2004) “Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees.”Hepatology39(6):1709-1720.
Meunier J.C. et al. (2005) “Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1.”PNAS USA102(12):4560-4565.
Ogata, N. et al. (1991) “Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.”PNAS USA88:3392-3396.
Okamoto, H. et al. (1992) “Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability.”Virology190:894-899.
Okamoto, H. et al. (1994) “Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a.”Hepatology20:1131-1136.
Rice, C.M. (2006) “Hepatitis C: progress toward new therapies from Third Annual PHRI Symposium.”, published 2006 and downloaded Jan. 23, 2006.
Su, A. et al. (2002) “Genomic analysis of the host response to hepatitis C virus infection.”PNAS USA99(24):15669-15674.
Thimme, R. et al. (2002) “Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.”PNAS USA99(24):15661-15668.
Weiner, A.J. et al. (2001) “Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity.”J. Virol.75(15):7142-7148.
Yanagi, M. et al. (1997) “Transcripts from a single full-length cDNA clone of Hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee.”PNAS USA94: 8738-8743.
Yanagi, M. et al. (1998) “Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo.”Virology244: 161-172 Apr. 25.
Yanagi, M. et al. (1999) “Hepatitis C virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras.”Virology262(1):250-263.
Yoo, B.J. et al. (1995) “Transfection of a differentiated human hepatoma cell line (Huh 7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV.”J. Virol.69:32-38, Jan. 1995.
Yu, M.-YW. et al. (2004) “Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma.”PNAS USA101(20):7705-7710.
Bukh Jens
Emerson Suzanne U.
Purcell Robert H.
Yanagi Masayuki
Marvich Maria B
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Cloned genomes of infectious hepatitis C viruses and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cloned genomes of infectious hepatitis C viruses and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cloned genomes of infectious hepatitis C viruses and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237658